Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873361 | 0.92 | HTR2A (0.33) | KDM4ESYKPKM | |
| SCHEMBL7884615 | 0.89 | LOXL2 (0.38) | — | |
| SCHEMBL7881828 | 0.89 | CLK1 (0.31) | CLK1CLK2CLK3GSK3BDYRK1A | |
| SCHEMBL7881928 | 0.86 | IDO1 (0.35) | CLK1CLK2CLK3GSK3BDYRK1A | |
| SCHEMBL7877759 | 0.85 | SLC6A4 (0.36) | PKM | |
| SCHEMBL7873655 | 0.85 | KDR (0.32) | KDM4EPKM | |
| SCHEMBL7881278 | 0.85 | PTPN11 (0.34) | KDM4ESYKPKM | |
| SCHEMBL7877615 | 0.85 | PPARG (0.34) | — | |
| SCHEMBL7880764 | 0.84 | ACHE (0.34) | — | |
| SCHEMBL7880880 | 0.84 | RHEB (0.39) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |